- France-South Korea €25M AI-biotech funding call supports 25 projects worldwide.
- Grants average €1M each, targeting drug discovery (45%) and genomics (30%).
- Applications due July 15, 2026; past winners saw 2.5x valuation uplift.
Key Takeaways
- France-South Korea €25M AI-biotech funding call supports 25 projects worldwide, averaging €1M grants each.
- Targets drug discovery (45%) and genomics (30%), covering 70% R&D costs for applicants.
- Applications close July 15, 2026; past winners achieved 2.5x valuation uplift and 35% revenue growth.
France and South Korea launched €25M AI-biotech funding call on April 13, 2026. It accelerates 25 global startups in drug discovery and genomics with grants up to €2M.
Nicolas Dufourcq, CEO of Bpifrance, announced it at a virtual event. "This bridges AI innovation across borders," Dufourcq said. South Korea's Minister Lee Jong-ho co-unveiled it, stressing tech transfer. Dr. Elena Vasquez, Biotech Lead at TechCrunch, deemed it "pivotal for cross-border AI-biotech scaling."
€25M AI-Biotech Funding Targets Drug Discovery and Genomics
Bpifrance's France 2030 plan and Korea's Digital New Deal fund the €25M pool. Grants range €500K-€2M for startups under 250 employees using AI in biotech, like AlphaFold3 protein folding and genomic sequencing.
Prior Bpifrance rounds funded 18 startups, averaging 35% revenue growth in year one, per Bpifrance data. OECD 2025 report lists 120 AI-biotech firms in France, 85 in South Korea. Scalable prototypes for Phase 1 trials boost success by 50% for AI users.
Crypto Crash Shifts Startups to €25M AI-Biotech Funding
Crypto Fear & Greed Index hit 12 on Alternative.me. Bitcoin fell 0.6% to $70,952 USD; Ethereum dropped 0.7% to $2,186 USD. PitchBook Q1 2026 data shows VCs withdrew $2.5B from AI-biotech.
Non-dilutive grants cover 70% R&D, cutting cash burn 40%. This call fills the VC gap, offering stability and 2.5x valuation potential amid turmoil.
€150M+ Prior Investments Bolster New AI-Biotech Funding
2025 France-Korea tech accord adds biotech to €150M Bpifrance AI funds and ₩300B ($220M USD) MSIT biotech AI through 2027. Projects require Paris-Seoul tech transfer.
MSIT pilots cut rare disease diagnostics 40%, per ministry data. EU Horizon benchmarks predict 500+ applications. Winners access Sanofi and Samsung Biologics, forecasting €100M revenue in five years.
Allocation: 45% Drug Discovery, 30% Genomics in AI-Biotech Funding
Drug discovery claims 45%, with AI speeding molecule prediction 25x. Genomics takes 30%, improving CRISPR 60%. Sustainable biotech (15%) eyes biofuels; diagnostics (10%) refines imaging.
Tips: Highlight AI novelty (40% score), impact (30%), commercialization (30%). Cross-border teams win 60% more, per Vasquez.
Deadlines and Implications of €25M AI-Biotech Funding
Pitches via Bpifrance portal by May 31, 2026; full proposals by July 15. France tax credits cover 30% expenses.
Investors eye winners for 35% revenue growth. Government backing amid VC retreat drives AI-biotech M&A at 2-3x multiples in 18 months.
